Loading...
Market
Story
Vaxcyte ($PCVX) Shares Surge 33% on Positive Pneumococcal Vaccine Data
Sep 3, 2024, 12:25 PM
Vaxcyte ($PCVX) has reported positive topline data from its Phase 1/2 study of VAX-31, a 31-valent pneumococcal conjugate vaccine candidate, in adults aged 50 and older. The data indicated that VAX-31 met or exceeded regulatory immunogenicity criteria at high and middle doses. Following this announcement, Vaxcyte's shares surged 33% in pre-market trading. The vaccine's safety profile was found to be similar to Pfizer's pneumococcal shot. VAX-31 aims to prevent invasive pneumococcal disease.
View original story
Similar markets
Below $10 billion • 25%
$10 billion - $15 billion • 25%
$15 billion - $20 billion • 25%
Above $20 billion • 25%
Below $100 • 25%
$100 to $120 • 25%
$120 to $140 • 25%
Above $140 • 25%
<$300 million • 25%
$300-500 million • 25%
$500-700 million • 25%
>$700 million • 25%
Below $5 billion • 25%
$5 billion to $6 billion • 25%
$6 billion to $7 billion • 25%
Above $7 billion • 25%
Less than $85 billion • 25%
$85 billion to $90 billion • 25%
$90 billion to $95 billion • 25%
More than $95 billion • 25%
Less than $200 million • 25%
$200 million to $300 million • 25%
$300 million to $400 million • 25%
More than $400 million • 25%
Less than $3 billion • 25%
$3 billion to $3.5 billion • 25%
$3.5 billion to $4 billion • 25%
More than $4 billion • 25%
Below $27.1 billion • 25%
$27.1 billion to $27.3 billion • 25%
$27.31 billion to $27.5 billion • 25%
Above $27.5 billion • 25%